236 related articles for article (PubMed ID: 20124184)
41. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
43. Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
Mattar A; Logullo AF; Facina G; Nonogaki S; Soares FA; Gebrim LH
J Cancer Res Clin Oncol; 2011 May; 137(5):897-905. PubMed ID: 20886231
[TBL] [Abstract][Full Text] [Related]
44. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Ghazoui Z; Buffa FM; Dunbier AK; Anderson H; Dexter T; Detre S; Salter J; Smith IE; Harris AL; Dowsett M
Clin Cancer Res; 2011 May; 17(9):3005-12. PubMed ID: 21325071
[TBL] [Abstract][Full Text] [Related]
45. Classification of breast cancer cells on the basis of a functional assay for estrogen receptor.
Biswas DK; Averboukh L; Sheng S; Martin K; Ewaniuk DS; Jawde TF; Wang F; Pardee AB
Mol Med; 1998 Jul; 4(7):454-67. PubMed ID: 9713824
[TBL] [Abstract][Full Text] [Related]
46. Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer.
Abul-Hajj YJ
Steroids; 1979 Aug; 34(2):217-25. PubMed ID: 494363
[TBL] [Abstract][Full Text] [Related]
47. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
48. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
[TBL] [Abstract][Full Text] [Related]
49. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Ingle JN; Buzdar AU; Schaid DJ; Goetz MP; Batzler A; Robson ME; Northfelt DW; Olson JE; Perez EA; Desta Z; Weintraub RA; Williard CV; Flockhart DA; Weinshilboum RM
Cancer Res; 2010 Apr; 70(8):3278-86. PubMed ID: 20354183
[TBL] [Abstract][Full Text] [Related]
50. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels.
Saez S; Martin PM; Chouvet CD
Cancer Res; 1978 Oct; 38(10):3468-73. PubMed ID: 688231
[TBL] [Abstract][Full Text] [Related]
51. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
52. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
53. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.
Geisler J; Berntsen H; Lonning PE
J Steroid Biochem Mol Biol; 2000 Apr; 72(5):259-64. PubMed ID: 10822015
[TBL] [Abstract][Full Text] [Related]
54. Primary hormone treatment in postmenopausal women with breast cancer.
Maciá Escalante S; Pons Sanz V; Rodríguez Lescure A; Ballester Navarro I; Carrato Mena A
Clin Transl Oncol; 2006 May; 8(5):372-4. PubMed ID: 16760014
[TBL] [Abstract][Full Text] [Related]
55. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
56. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
Olsson H; Borg A; Ewers SB; Fernö M; Möller T; Ranstam J
Med Oncol Tumor Pharmacother; 1986; 3(2):77-81. PubMed ID: 3747639
[TBL] [Abstract][Full Text] [Related]
57. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Freedman OC; Amir E; Hanna W; Kahn H; O'Malley F; Dranitsaris G; Cole DE; Verma S; Folkerd E; Dowsett M; Clemons M
Breast Cancer Res Treat; 2010 Jan; 119(1):155-61. PubMed ID: 19731013
[TBL] [Abstract][Full Text] [Related]
58. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
59. Role of biologic markers in patient selection and application to disease prevention.
Dowsett M; Ellis MJ
Am J Clin Oncol; 2003 Aug; 26(4):S34-9. PubMed ID: 12902875
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
